Research progress on the role of gut microbiota dysbiosis in the pathogenesis of immune-mediated liver diseases - PubMed
5 hours ago
- #microbiota dysbiosis
- #gut-liver axis
- #immune-mediated liver diseases
- Gut microbiota dysbiosis contributes to immune-mediated liver diseases (IMLDs) like AIH, PBC, and PSC via the gut-liver axis.
- Microbial metabolites (SCFAs, bile acids) regulate liver immunity through GPRs and FXR receptors.
- Intestinal barrier disruption allows endotoxins to activate hepatic macrophages via TLR4/NF-κB, causing inflammation.
- Specific microbial imbalances are linked to diseases: Veillonella in AIH, Enterobacteriaceae/Oscillospira shifts in PBC, and Klebsiella/Candida in PSC.
- Therapies like FMT, probiotics, prebiotics, and bacteriophages show promise in treating IMLDs.
- Future research should explore immune cell regulation by gut-derived factors and precision therapies.